Anaplastic thyroid carcinoma;Cancers anaplasiques de la thyroïde

Annales d'Endocrinologie

Volumn 69, Issue 3, 2008, Pages 174-180

  Wemeau, J L ^a   Do Cao, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anaplastic; Chemotherapy; Radiotherapy; Thyroid cancer

Indexed keywords

ALPRAZOLAM; ATROPINE; BENZODIAZEPINE; BLEOMYCIN; BROMAZEPAM; BROMIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LORAZEPAM; MIDAZOLAM; PACLITAXEL; SCOPOLAMINE;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; MONOTHERAPY; SHORT SURVEY; THYROID CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; GOITER; HUMANS; MIDDLE AGED; THYROID DISEASES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 45249124454     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2008.02.003     Document Type: Short Survey

References (48)

1. Gilliland F.D., Hunt W.C., Morris D.M., and Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program (1973-1991). Cancer 79 (1997) 564-573
2. Schlumberger M.P. Thyroid tumors. Anaplastic thyroid cancinoma (2003), Nucleon, Paris
3. Lampertico P. Anaplastic (sarcomatoid) carcinoma of the thyroid gland. Semin Diagn Pathol 10 (1993) 159-168
4. Crile Jr. G. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer 10 (1957) 1119-1137
5. Venkatesh Y.S., Ordonez N.G., Schultz P.N., Hickey R.C., Goepfert H., and Samaan N.A. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66 (1990) 321-330
6. Williams E.S.D. Thyroid cancer: pathologic and natural history. Cancer Res 73 (1980) 47-55
7. Are C., and Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13 (2006) 453-464
8. Lemoine N.R., Mayall E.S., Wyllie F.S., Williams E.D., Goyns M., Stringer B., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4 (1989) 159-164
9. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., and Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91 (1993) 1753-1760
10. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., and Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91 (1993) 179-184
11. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52 (1992) 1369-1371
12. Battista S., Martelli M.L., Fedele M., Chiappetta G., Trapasso F., De Vita G., et al. A mutated p53 gene alters thyroid cell differentiation. Oncogene 11 (1995) 2029-2037
13. Takano T., Ito Y., Hirokawa M., Yoshida H., and Miyauchi A. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96 (2007) 1549-1553
14. McIver B., Hay I.D., Giuffrida D.F., Dvorak C.E., Grant C.S., Thompson G.B., et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130 (2001) 1028-1034
15. Pasieka J.L. Anaplastic thyroid cancer. Curr Opin Oncol 15 (2003) 78-83
16. Basaria S., Udelsman R., Tejedor-Sojo J., Westra W.H., and Krasner A.S. Anaplastic pseudothyroiditis. Clin Endocrinol (Oxf) 56 (2002) 553-555
17. Tennvall J., Lundell G., Wahlberg P., Bergenfelz A., Grimelius L., Akerman M., et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86 (2002) 1848-1853
18. Besic N., Hocevar M., Zgajnar J., Pogacnik A., Grazio-Frkovic S., and Auersperg M. Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 390 (2005) 203-208
19. Us-Krasovec M., Golouh R., Auersperg M., Besic N., and Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 40 (1996) 953-958
20. Giuffrida D., and Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11 (2000) 1083-1089
21. Sarlis N.J. Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Rev Endocr Metab Disord 1 (2000) 183-196
22. Sugitani I., Kasai N., Fujimoto Y., and Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25 (2001) 617-622
23. Brignardello E., Gallo M., Baldi I., Palestini N., Piovesan A., Grossi E., et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156 (2007) 425-430
24. Carcangiu M.L., Steeper T., Zampi G., and Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83 (1985) 135-158
25. Kobayashi T., Asakawa H., Umeshita K., Takeda T., Maruyama H., Matsuzuka F., et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18 (1996) 36-41
26. Besic N., Auersperg M., Us-Krasovec M., Golouh R., Frkovic-Grazio S., and Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27 (2001) 260-264
27. Ahuja S., and Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10 (1987) 303-310
28. Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., and DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (1985) 2155-2160
29. Williams S.D., Birch R., and Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70 (1986) 405-407
30. De Besi P., Busnardo B., Toso S., Girelli M.E., Nacamulli D., Simioni N., et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14 (1991) 475-480
31. Satake S., Sugawara I., Watanabe M., and Takami H. Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 116 (1997) 33-39
32. Ain K.B., Egorin M.J., and DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10 (2000) 587-594
33. Tennvall J., Lundell G., Hallquist A., Wahlberg P., Wallin G., and Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 74 (1994) 1348-1354
34. De Crevoisier R., Baudin E., Bachelot A., Leboulleux S., Travagli J.P., Caillou B., et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1137-1143
35. Pierie J.P., Muzikansky A., Gaz R.D., Faquin W.C., and Ott M.J. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9 (2002) 57-64
36. Haigh P.I., Ituarte P.H., Wu H.S., Treseler P.A., Posner M.D., Quivey J.M., et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91 (2001) 2335-2342
37. Lu W.T., Lin J.D., Huang H.S., and Chao T.C. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma?. Otolaryngol Head Neck Surg 118 (1998) 728-731
38. Sugino K., Ito K., Mimura T., Nagahama M., Fukunari N., Kubo A., et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131 (2002) 245-248
39. Kim J.H., and Leeper R.D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60 (1987) 2372-2375
40. Tallroth E., Wallin G., Lundell G., Läwhagen T., and Einhorn J. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 60 (1987) 1428-1431
41. Nagayama Y., Yokoi H., Takeda K., Hasegawa M., Nishihara E., Namba H., et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85 (2000) 4081-4086
42. Imanishi R., Ohtsuru A., Iwamatsu M., Iioka T., Namba H., Seto S., et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab 87 (2002) 4821-4824
43. Xu G., Pan J., Martin C., and Yeung S.C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86 (2001) 1769-1777
44. Dowlati A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 (2002) 3408-3416
45. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J Natl Cancer Inst 92 7 (2000) 520-522
46. Schiff B.A., McMurphy A.B., Jasser S.A., Younes M.N., Doan D., Yigitbasi O.G., et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10 (2004) 8594-8602
47. Fury M.G., Solit D.B., Su Y.B., Rosen N., Sirotnak F.M., Smith R.P., et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59 (2007) 467-475
48. Kurebayashi J., Okubo S., Yamamoto Y., Ikeda M., Tanaka K., Otsuki T., et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58 (2006) 460-470